Canada (CA)

rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology (2018) Kelemen LE, Earp M, Fridley BL, Chenevix-Trench G, Fasching P, Beckmann M, Ekici AB, et al. Journal article Effect of Seladelpar on Pruritus in Primary Biliary Cholangitis: 26-Week Analysis of an Ongoing International, randomized, Dose Ranging Phase 2 Study (2018) Kremer A, Bowlus CL, Neff GW, Aspinall R, Galambos MR, Goel A, Hirschfield G, et al. Conference contribution Final analysis of time to subsequent disease progression/death in patients with metastatic enteropancreatic neuroendocrine tumours progressing under placebo and switched to lanreotide Autogel/depot 120mg in the CLARINET open-label extension (2018) Pavel ME, Cwikla J, Wolin E, Phan A, Raderer M, Sedlackova E, Cadiot G, et al. Conference contribution ElevatION: NET-201 A Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients with Metastatic, Well-Differentiated NET of Pancreatic/GI/Thoracic Origin or Poorly-Differentiated GEP NEC Who Have Progressed on Prior Treatment (2018) Yao JC, Fazio N, Li D, Pavel ME, Strosberg J, Bergsland E, Ruszniewski P, et al. Conference contribution Systemic Markers of Inflammation in Neuroendocrine Tumors (NETs) and Outcomes with Everolimus: A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials (2018) Chan DL, Yao JC, Carnaghi C, Buzzoni R, Herbst F, Ridolfi A, Strosberg J, et al. Conference contribution The validity of the Cracow Instrument in the prediction of antisocial development in preschool children: A five-year longitudinal community based study (2018) Wallner S, Lösel F, Stemmler M, Corrado R Journal article, Original article 5-YEAR EFFICACY AND SAFETY OF APREMILAST TREATMENT IN SUBJECTS WITH PSORIATIC ARTHRITIS: POOLED ANALYSIS OF THE PALACE STUDIES (2018) Kavanaugh A, Gladman DD, Edwards CJ, Schett G, Guerette B, Delev N, Teng L, et al. Conference contribution Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis: Long-Term (4-Year) Data from a Phase 3 Study (2018) Mcinnes IB, Kivitz AJ, Nash P, Rahman P, Rech J, Kirkham B, Navarra SV, et al. Conference contribution Durability of apremilast response through 5 years of treatment in subjects with psoriatic arthritis (2018) Kavanaugh A, Gladman DD, Gomez-Reino JJ, Hall S, Lespessailles E, Mease PJ, Schett G, et al. Conference contribution Factors Influencing Central Lamina Cribrosa Depth: A Multicenter Study (2018) Luo H, Yang H, Gardiner SK, Hardin C, Sharpe GP, Caprioli J, Demirel S, et al. Journal article